Susquehanna Fundamental Investments’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,867	Closed	-$669K	–	1943
2021 Q2	$669K	Hold	5,867	–	–	0.01%	1039
2021 Q1	$705K	Hold	5,867	–	–	0.01%	1018
2020 Q4	$596K	Sell	5,867 -13,600	-70%	-$1.26M	0.01%	1037
2020 Q3	$1.5M	Buy	19,467 +7,267	+60%	+$619K	0.04%	516
2020 Q2	$1.36M	Buy	+12,200	New	+$1.06M	0.07%	382

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Susquehanna Fundamental Investments's KRTX Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2021, closing a stake of 5,867 shares — an estimated $669K sold.

Susquehanna Fundamental Investments first reported a position in KRTX in Q2 2020 and held it in 5 quarters. The position peaked at $1.5M in Q3 2020. 159 funds tracked by Wall St. Rank hold KRTX as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 5,867 Karuna Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $669K.
Susquehanna Fundamental Investments first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Susquehanna Fundamental Investments's Karuna Therapeutics, Inc. Common Stock position peaked at $1.5M in Q3 2020.
159 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.